Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 19/20 | 0.67 |
| ▸ | FPR1 | P21462 | 1/20 | 0.60 |
| ▸ | GPR183 | P32249 | 1/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5764978 | 0.89 | GNRHR (0.72) | GNRHRFPR1GPR183GPR119RXRA | |
| SCHEMBL6266167 | 0.88 | GNRHR (0.53) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL5834269 | 0.87 | GNRHR (0.53) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL5834348 | 0.85 | GNRHR (0.68) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL6265058 | 0.84 | GNRHR (0.57) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL6268898 | 0.84 | GNRHR (0.50) | GNRHRFPR1GPR183GPR119RXRA | |
| SCHEMBL5040244 | 0.80 | GNRHR (0.57) | GNRHRFPR1GPR183GPR119RXRA | |
| SCHEMBL24441357 | 0.80 | GNRHR (0.63) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL6226419 | 0.79 | GNRHR (0.68) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL5766856 | 0.78 | GNRHR (0.55) | GNRHRFPR1GPR183GPR119RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101878-B1 | Non-peptide GNRH agents, methods and intermediates for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050250846-A1 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | ANDERSON MARK B | 2005-11-10 | — | — | US | disclosed |
| EP-1560818-A1 | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-08-10 | — | — | EP | disclosed |
| US-6903132-B2 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1105120-B1 | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | AGOURON PHARMA (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040014787-A1 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040010033-A1 | Non-peptide GnRH agents, methods and intermediates for their preparation | PFIZER INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003106446-A1 | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-1105120-A4 | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | AGOURON PHARMA (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-1105120-A2 | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000020358-A2 | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250846-A1 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | GNRHR, LHCGR, FSHR | GNRHR 1/4885FPR1 1988/4885GPR183 293/4885 |
| US-20040014787-A1 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | GNRHR, LHCGR, FSHR | GNRHR 1/4885FPR1 1988/4885GPR183 293/4885 |
| US-20040010033-A1 | Non-peptide GnRH agents, methods and intermediates for their preparation | GNRHR, FSHR, LHCGR | GNRHR 1/4885FPR1 2087/4885GPR183 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.